A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma

References

• Cancer Research UK. Multiple myeloma; 2020 Available from: https://www.cancerresearchuk.org/about-cancer/myeloma/about
   Google Scholar
• Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Hemasphere. 2021;5(2):e528.
   PubMed Web of Science ®Google Scholar
• Ito S. Proteasome inhibitors for the treatment of multiple myeloma. Cancers. 2020;12(2):265. doi:10.3390/cancers12020265
   PubMed Web of Science ®Google Scholar
• Mikhael J. Treatment options for triple-class refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20(1):1–7. doi:10.1016/j.clml.2019.09.621
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Multiple Myeloma Version 3.2023. November 23 2022. (https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf).
   Google Scholar
• Padala SA, Barsouk A, Barsouk A, et al. Epidemiology, staging, and management of multiple myeloma. Med Sci. 2021;9(1):3.
   Google Scholar
• Cornell RF, Kassim AA. Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity. Bone Marrow Transplant. 2016;51(4):479–491. doi:10.1038/bmt.2015.307
   PubMed Web of Science ®Google Scholar
• Kumar SK, Therneau TM, Gertz MA, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc. 2004;79(7):867–874. doi:10.4065/79.7.867
   PubMed Web of Science ®Google Scholar
• Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266–2275. doi:10.1038/s41375-019-0435-7
   PubMed Web of Science ®Google Scholar
• Bal S, Malek E, Kansagra A, et al. Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies. Leukemia. 2022;36(3):877–880. doi:10.1038/s41375-021-01471-3
   PubMed Web of Science ®Google Scholar
• Mateos MV, Weisel K, De Stefano V, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia. 2022;36(5):1371–1376. doi:10.1038/s41375-022-01531-2
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA grants accelerated approval to elranatamab-bcmm for multiple myeloma. (https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-elranatamab-bcmm-multiple-myeloma)
   Google Scholar
• Kociszewska K, Bednarczyk M, Grosicki S. Elranatamab: a new promising BispAb in multiple myeloma treatment. Expert Rev Anticancer Ther. 2023;23(8):775–782. doi:10.1080/14737140.2023.2236303
   PubMed Web of Science ®Google Scholar
• Landgren O, Nadeem O. Bispecific monoclonal antibodies in multiple myeloma: data from ASH 2022: a podcast. Adv Ther. 2023;40(8):3291–3303. doi:10.1007/s12325-023-02551-9
   PubMed Web of Science ®Google Scholar
• Tanenbaum B, Miett T, Patel SA. The emerging therapeutic landscape of relapsed/refractory multiple myeloma. Ann Hematol. 2023;102(1):1–11. doi:10.1007/s00277-022-05058-5
   PubMed Web of Science ®Google Scholar
• Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29(9):2259–2267. doi:10.1038/s41591-023-02528-9
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Summary of Product Characteristics: Nexpovio. Amsterdam: May 27 2021. (https://www.ema.europa.eu/en/medicines/human/EPAR/nexpovio)
   Google Scholar
• European Medicines Agency. Summary of Product Characteristics: Abecma. Amsterdam: August 25 2021. (https://www.ema.europa.eu/en/medicines/human/EPAR/abecma)
   Google Scholar
• Kleber M, Ntanasis-Stathopoulos I, Terpos E. BCMA in multiple myeloma—a promising key to therapy. J Clin Med. 2021;10(18):4088. doi:10.3390/jcm10184088
   PubMed Web of Science ®Google Scholar
• Phillippo DM, Ades AE, Dias S, et al. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200–211. doi:10.1177/0272989X17725740
   PubMed Web of Science ®Google Scholar
• Remiro-Azócar A, Heath A, Baio G. Methods for population adjustment with limited access to individual patient data: a review and simulation study. Res Synth Methods. 2021;12(6):750–775. doi:10.1002/jrsm.1511
   PubMed Web of Science ®Google Scholar
• Guyot P, Ades AE, Ouwens MJNM, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Medical Research Methodology 2012;12(1):9. DOI: 10.1186/1471-2288-12-9.
   Google Scholar
• Ishak KJ, Proskorovsky I, Benedict A. Simulation and matching-based approaches for indirect comparison of treatments. Pharmacoeconomics. 2015;33(6):537–549. doi:10.1007/s40273-015-0271-1
   PubMed Web of Science ®Google Scholar
• Sidana S, Moreau P, Garfall AL, et al. Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) × CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). Hemasphere. 2023;7(Suppl.):e62475d0.
   Google Scholar
• Moreau P, Garfall AL, van de Donk N, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495–505. doi:10.1056/NEJMoa2203478
   PubMed Web of Science ®Google Scholar
• Phillippo D, Ades T, Dias S, et al. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE. NICE Decision Support Unit. Sheffield: University of Sheffield; 2016. p. 82.
   Google Scholar
• Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2):207–221. doi:10.1016/S1470-2045(19)30788-0
   PubMed Web of Science ®Google Scholar
• Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314–324. doi:10.1016/S0140-6736(21)00933-8
   PubMed Web of Science ®Google Scholar
• Munshi NC, Anderson LDJr., Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–716. doi:10.1056/NEJMoa2024850
   PubMed Web of Science ®Google Scholar
• Shah N, Chari A, Scott E, et al. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34(4):985–1005. doi:10.1038/s41375-020-0734-z
   PubMed Web of Science ®Google Scholar
• Sanoyan DA, Seipel K, Bacher U, et al. Real-life experiences with CAR T-cell therapy with idecabtagene ­vicleucel (ide-cel) for triple-class exposed relapsed/­refractory multiple myeloma patients. BMC Cancer. 2023;23(1):345. doi:10.1186/s12885-023-10824-3
   PubMed Web of Science ®Google Scholar
• Jakobsen JC, Gluud C, Wetterslev J, et al. When and how should multiple imputation be used for handling missing data in randomised clinical trials – a practical guide with flowcharts. BMC Med Res Methodol. 2017;17(1):162. doi:10.1186/s12874-017-0442-1
   PubMed Web of Science ®Google Scholar